BioWa Licenses POTELLIGENT™ Technology to Genentech
News Mar 27, 2006
BioWa, Inc. has announced that it licensed to Genentech, Inc. its POTELLIGENT™ technology for use in researching and developing select Genentech antibodies for potential therapeutic applications that may include enhancement of antibody-dependent cellular cytotoxicity (ADCC).
"Genentech is an unparalleled market leader in the field of antibody therapeutics," said Dr. Nobuo Hanai, BioWa President and CEO.
"We believe this is an important opportunity to aid the development of more effective targeted treatments for cancer and other life-threatening and debilitating diseases."
Under the terms of the agreement, BioWa will provide Genentech with exclusive commercial rights to use the technology for multiple antibodies.
In return, BioWa will receive technology access fees, and may receive milestone payments and royalties in the event that products are developed by Genentech. Additional terms were not disclosed.
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE